Two Sigma Advisers’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-735
| Closed | -$8.61K | – | 2755 |
|
|
2023
Q1 | $8.61K | Sell |
735
-15
| -2% | -$249 | ﹤0.01% | 2549 |
|
|
2022
Q4 | $11.5K | Buy |
750
+10
| +1% | +$117 | ﹤0.01% | 2453 |
|
|
2022
Q3 | $4K | Buy |
740
+20
| +3% | +$167 | ﹤0.01% | 2506 |
|
|
2022
Q2 | $7K | Hold |
720
| – | – | ﹤0.01% | 2602 |
|
|
2022
Q1 | $23K | Sell |
720
-145
| -17% | -$5.7K | ﹤0.01% | 2661 |
|
|
2021
Q4 | $41K | Buy |
865
+265
| +44% | +$18.3K | ﹤0.01% | 2488 |
|
|
2021
Q3 | $55K | Buy |
+600
| New | +$49.8K | ﹤0.01% | 2367 |
|
|
2020
Q3 | – | Sell |
-4,032
| Closed | -$355K | – | 2696 |
|
|
2020
Q2 | $355K | Buy |
4,032
+26
| +0.6% | +$2.75K | ﹤0.01% | 2045 |
|
|
2020
Q1 | $448K | Sell |
4,006
-95
| -2% | -$18.7K | ﹤0.01% | 1849 |
|
|
2019
Q4 | $1M | Buy |
4,101
+846
| +26% | +$213K | ﹤0.01% | 1578 |
|
|
2019
Q3 | $1.12M | Buy |
3,255
+314
| +11% | +$171K | ﹤0.01% | 1382 |
|
|
2019
Q2 | $2.71M | Buy |
2,941
+702
| +31% | +$863K | 0.01% | 1081 |
|
|
2019
Q1 | $3.57M | Buy |
2,239
+876
| +64% | +$1.58M | 0.01% | 956 |
|
|
2018
Q4 | $2.55M | Buy |
1,363
+355
| +35% | +$773K | 0.01% | 1068 |
|
|
2018
Q3 | $2.38M | Sell |
1,008
-740
| -42% | -$2.29M | 0.01% | 1145 |
|
|
2018
Q2 | $6.02M | Buy |
1,748
+285
| +19% | +$873K | 0.02% | 775 |
|
|
2018
Q1 | $4.15M | Sell |
1,463
-394
| -21% | -$1.18M | 0.01% | 927 |
|
|
2017
Q4 | $4.78M | Sell |
1,857
-354
| -16% | -$1.01M | 0.01% | 864 |
|
|
2017
Q3 | $6.27M | Sell |
2,211
-1,065
| -33% | -$2.81M | 0.02% | 714 |
|
|
2017
Q2 | $7.74M | Buy |
3,276
+161
| +5% | +$319K | 0.03% | 593 |
|
|
2017
Q1 | $7.85M | Buy |
3,115
+205
| +7% | +$590K | 0.03% | 651 |
|
|
2016
Q4 | $6.56M | Buy |
2,910
+500
| +21% | +$1.19M | 0.03% | 615 |
|
|
2016
Q3 | $6.04M | Sell |
2,410
-583
| -19% | -$1.74M | 0.03% | 579 |
|
|
2016
Q2 | $9.16M | Buy |
2,993
+461
| +18% | +$1.5M | 0.05% | 390 |
|
|
2016
Q1 | $8.04M | Buy |
2,532
+1,608
| +174% | +$6.68M | 0.05% | 385 |
|
|
2015
Q4 | $4.74M | Buy |
+924
| New | +$4.04M | 0.03% | 460 |
|
|
2015
Q3 | – | Sell |
-184
| Closed | -$736K | – | 2032 |
|
|
2015
Q2 | $736K | Sell |
184
-581
| -76% | -$2.24M | 0.01% | 1252 |
|
|
2015
Q1 | $3.06M | Buy |
765
+483
| +171% | +$2.21M | 0.02% | 626 |
|
|
2014
Q4 | $1.39M | Sell |
282
-131
| -32% | -$562K | 0.01% | 993 |
|
|
2014
Q3 | $1.68M | Buy |
413
+43
| +12% | +$161K | 0.01% | 866 |
|
|
2014
Q2 | $1.5M | Buy |
370
+39
| +12% | +$159K | 0.01% | 961 |
|
|
2014
Q1 | $1.5M | Buy |
331
+219
| +196% | +$885K | 0.01% | 907 |
|
|
2013
Q4 | $391K | Buy |
+112
| New | +$437K | ﹤0.01% | 1750 |
|
Other funds holding ACOR
DKCM
Two Sigma Advisers's ACOR Position: Q2 2023 in Review
Two Sigma Advisers sold out of Acorda Therapeutics (ACOR) in Q2 2023, closing a stake of 735 shares — an estimated $8.61K sold.
Two Sigma Advisers first reported a position in ACOR in Q4 2013 and held it in 33 quarters. The position peaked at $9.16M in Q2 2016. 15 funds tracked by Wall St. Rank hold ACOR as of Q2 2023.
- Two Sigma Advisers reported no remaining Acorda Therapeutics position as of Q2 2023 after selling out during the quarter.
- Two Sigma Advisers sold 735 Acorda Therapeutics shares in Q2 2023, an estimated $8.61K.
- Two Sigma Advisers first reported a position in Acorda Therapeutics in Q4 2013 and held it in 33 quarters.
- Two Sigma Advisers's Acorda Therapeutics position peaked at $9.16M in Q2 2016.
- 15 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2023.
Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.